Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma Inc. : - Science-Based Fitness Service, Fit-eNce

08/24/2020 | 08:49am EST

TOKYO - Astellas Pharma Inc. (Tokyo, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') announced today that it will start accepting advance applications and taking reservations for its exercise support service Fit-eNce1, which encourages continous implementation of science-based exercise programs2.

The service is planned to be offered in limited areas from September 1 through fitness clubs in Kanagawa Prefecture.

Exercise therapy is reported to be beneficial as a treatment for various diseases including type 2 diabetes. However, it is often difficult for physicians to offer specific guidance on exercise therapy or to be aware of all of the exercises that a patient performs. Meanwhile, it is difficult for patients to know which exercise programs are appropriate and to maintain the motivation to exercise, which brings challenge in starting and continuing exercise. Fit-eNce is a new exericse support service designed to resolve these issues by helping patients to continuously implement science-based exercise programs under the guidance of physicians.

With this service, patients who have been referred to the service by a physician submit an application to enroll in the service through a dedicated smartphone app and receive physician approval for use of the service. Patients then register with the affiliated fitness club to begin exercising. At the fitness club, trainers will suggest a lineup of exercises tailored to the patient's physical condition (age, muscular strength, physical strength, etc.), on the basis of science-based exercise programs that combine aerobic exercise with resistance exercise (repetitive exercises that exert resistance on target muscles) for the patient to perform. Patients will be able to share their exercise records with their physician through the smartphone app, and physicians will be able to check their patients' frequency of fitness club use, exercise history, and goal achievement on a dedicated website. By using this website to check on their patients' daily exercise status and enhancing communication, it allows the physicians to support patients in contuining to exercise.

Fit-eNce is created with aims to generate and provide evidence-based healthcare solutions through the integration of medicine and exercise as a part of Astellas' Rx+ Business3. Astellas will continue to strive towards the realization of a society where appropriate exercise is practiced and people can live true to themselves, healthy in both mind and body.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.


Tel: +81-3-3244-3201

Fax: +81-3-5201-7473

(C) 2020 Electronic News Publishing, source ENP Newswire

01/14ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused ..
01/06ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Applicatio..
2020ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial
2020ASTELLAS PHARMA : Reports XOSPATA in Combination with Azacitidine Did Not Meet E..
2020ASTELLAS PHARMA : Supports Recommendations of Task Force on Climate-related Fina..
2020ASTELLAS PHARMA INC. : - Expansion of the Domestic Logistics Platform for Pharma..
2020VIATRIS : Astellas and Viatris Announce Termination of Co-promotion, Succession ..
2020Japan shares slip for third day; all eyes on U.S. stimulus debate
2020Japanese shares slip back as investors look to U.S. stimulus debate
2020Astellas Pharma, Viatris Pharmaceuticals Japan to End Joint Sales Promotion o..
More news
Sales 2021 1 272 B 12 253 M 12 253 M
Net income 2021 181 B 1 744 M 1 744 M
Net cash 2021 440 B 4 239 M 4 239 M
P/E ratio 2021 17,0x
Yield 2021 2,50%
Capitalization 3 130 B 30 155 M 30 153 M
EV / Sales 2021 2,11x
EV / Sales 2022 1,93x
Nbr of Employees 15 883
Free-Float 99,2%
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 268,18 JPY
Last Close Price 1 685,00 JPY
Spread / Highest target 114%
Spread / Average Target 34,6%
Spread / Lowest Target -2,08%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159